Anika Therapeutics traded at $14.55 this Friday November 6th, decreasing $4.78 or 24.73 percent since the previous trading session. Looking back, over the last four weeks, Anika Therapeutics lost 25.50 percent. Over the last 12 months, its price rose by 47.72 percent. Looking ahead, we forecast Anika Therapeutics to be priced at 20.51 by the end of this quarter and at 19.23 in one year, according to Trading Economics global macro models projections and analysts expectations.
Anika Therapeutics, Inc. is a joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. It is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform. Its product categories include joint pain management therapies, joint preservation and restoration care, and Other. The joint pain management therapies offer injectable viscosupplement products that provide pain relief from osteoarthritis conditions and its products include MONOVISC, ORTHOVISC, CINGAL and HYVISC. Its joint preservation and restoration care products include HYALOFAST and TACTOSET. Its Other product family consists of Hyalobarrier and Hyaloglide.